Atrioventricular Node Dysfunction in Heart Failure: New Horizons from Pathophysiology to Therapeutic Perspectives
Isabella Fumarulo1,2, Elia Nunzio Maria Salerno1,2, Andrea De Prisco1,2
1Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Journal of Cardiovascular Development and Disease
|August 27, 2025
Summary
Heart failure (HF) involves adverse remodeling of heart muscle and conduction tissue. This review explores atrioventricular (AV) node dysfunction in HF, its clinical impact, and current/future treatments.
Area of Science:
- Cardiology
- Electrophysiology
- Heart Failure Research
Background:
- Heart failure (HF) involves adverse myocardial remodeling affecting both cardiomyocytes and cardiac conduction system.
- Atrioventricular (AV) node dysfunction is a common complication in HF, causing conduction delays and dyssynchrony.
- Clinical outcomes in HF patients are often linked to AV node dysfunction, yet its pathology is under-explored.
Purpose of the Study:
- To investigate the pathophysiology of AV node dysfunction in the context of HF.
- To elucidate the clinical implications of AV node dysfunction for HF patients.
- To review current therapeutic strategies and explore potential future treatments for AV node dysfunction in HF.
Main Methods:
- Literature review of existing studies on HF and AV node pathology.
- Analysis of pathophysiological mechanisms linking HF and AV node dysfunction.
- Synthesis of clinical data regarding AV node dysfunction outcomes in HF.
Main Results:
- HF-induced remodeling significantly impacts AV node structure and function.
- AV node dysfunction contributes to arrhythmias and poor prognosis in HF.
- Current treatments offer limited efficacy for AV node-specific pathology in HF.
Conclusions:
- Understanding AV node pathophysiology in HF is crucial for improving patient outcomes.
- Targeting AV node dysfunction presents a potential therapeutic avenue for HF.
- Further research is needed to develop effective treatments for AV node pathology in HF.
More Related Videos
Related Concept Videos
Heart Failure II: Pathophysiology
37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
Cardiomyopathy II: Dilated Cardiomyopathy
21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Pathophysiology of Cardiac Performance
799
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
799


